Last reviewed · How we verify
BOTULISM ANTITOXIN
At a glance
| Generic name | BOTULISM ANTITOXIN |
|---|---|
| Modality | Recombinant protein |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients (PHASE4)
- Safety Study of 7 Botulinum Antitoxin Serotypes Derived From Horses (PHASE1)
- Botulism Antitoxin Effects on Paralysis Induced by Botulinum Neurotoxins in the EDB Muscle (PHASE1)
- BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum Antitoxin
- Treatment of Survivors After Botulism Outbreak
- Botulism Outbreak in Thailand (Episode II)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |